Trial Profile

A Phase 1/2 Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 7MW3711 in Subjects With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 13 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 7MW 3711 (Primary)
Indications Lung cancer; Non-small cell lung cancer; Oesophageal cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Mabwell (Shanghai) Bioscience

14 Oct 2025 According to Mabwell (Shanghai) Bioscience media release, as of Sep. 15, 2025, 74 patients with advanced solid tumor were enrolled and treated with 7MW3711 in the phase I/II study.
14 Oct 2025 According to Mabwell (Shanghai) Bioscience media release, data from this study will be presented as a poster at the European Society for Medical Oncology (ESMO) Congress 2025.
14 Oct 2025 Results presented in Mabwell (Shanghai) Bioscience media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com